Reading a preclinical wound-healing model and its relevance to a human tendon posts 61–90
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Anecdote is the whole of the human evidence base here, and this community's convention is to say so rather than to aggregate anecdotes into something that sounds like data.
That is the honest state of it as of this week.
Post #60 is right about the mechanism and I think understates the practical bit.
I have no financial interest in anything named in this thread and I want to say so before I comment on reading a preclinical wound-healing model, because it is the sort of subject where it matters.
Dose-response is unstudied in humans for essentially everything in this family, which means the confident numbers in circulation came from somewhere other than a trial.
It is the kind of thing that is obvious once and never again.
On post #62 — agreed on the reasoning, with one qualification.
The absence of adequately powered published randomised human trials is the central fact about BPC-157. This site states that plainly rather than hedging. Mechanistic plausibility does not substitute for it.
Where I would look next, rather than where I would stop.
Oral versus injected administration claims for BPC-157: the preclinical work studied injection. Oral claims are common in supplier marketing and poorly supported by published evidence. If you are comparing orality between compounds, that is a distinction worth noting.
Adding the measurement that post #67 says would settle it.
Marking my uncertainty on reading a preclinical wound-healing model explicitly. I am confident about the direction, much less confident about the size, and not confident at all that it generalises past the case in the first post.
Collapsed as off-topic by two members at trust level 3 or above
Post #66 describes the usual case. This is about the unusual one.
If someone has run reading a preclinical wound-healing model properly I would rather read that than my own reconstruction of it. Posting mine only because the thread has gone quiet.
For anyone arriving from search engines: this subcategory discusses published preclinical work and the absence of published clinical work. It does not endorse or recommend these compounds.
Adding this to the thread rather than to the wiki, because I am not confident enough for the wiki.
Confirming post #69 from a second method, which matters more than confirming it from a second person.
Adding a reference point for reading a preclinical wound-healing model. Mine is a single case, collected without controls, and I am posting the method alongside it so it can be discounted appropriately.
I would call the community position on reading a preclinical wound-healing model likely rather than established, and I would be comfortable defending that hedge.
Reported local reactions are common enough in first-hand accounts here to be worth mentioning and are not characterised in any published series.
I have said this before in a thread nobody could find, so it is worth repeating.
Understood. Thank you for being specific about the limits of it.
Post #73 is right about the mechanism and I think understates the practical bit.
One more thing on reading a preclinical wound-healing model that took me far too long to see: the two figures people quote are not measuring the same quantity. Once you notice that, the apparent contradiction disappears.
The pentadecapeptide sequence is short and stable enough to survive conditions that would degrade a larger peptide, which is one of the few things about it that is well characterised.
The general answer and the answer for your case may diverge here.
I read post #77 twice before replying, because I had assumed the opposite.
On reading a preclinical wound-healing model I would separate what is worth knowing from what is worth acting on. The first list is long and the second is short, and conflating them is how threads get heated.
BPC-157: the preclinical literature is extensive, mostly from a small number of research groups, and reports effects across a wide range of injury models. The breadth of reported effects is itself worth noting — a compound that improves outcomes in tendon, muscle, gut, nerve and bone through a single mechanism would be remarkable, and remarkable claims deserve proportionate scrutiny.
A guess, clearly labelled as one.
Post hidden by community flags
Staff rationale: Hidden by community flags. Described a research-use-only compound as approved for human use after a correction earlier in this topic (R4).
Reading a preclinical wound-healing model: the model shows whether a mechanism is plausible in a specific context. It does not show magnitude of effect in humans, does not show safety profile in humans, and does not show whether the effect survives in a more complex biological system. That is not a criticism of preclinical work — it is what preclinical work is for.
Happy to be corrected if someone holds better data than mine.
The corresponding entry is in the public moderation log. Hidden posts are never deleted.
The version of reading a preclinical wound-healing model that I was taught turned out to be a teaching simplification. Useful, and not true in the way I had assumed it was.
Answering the question post #80 raises rather than the one it answers.
One caution on reading a preclinical wound-healing model: everything above assumes the underlying documentation is what it claims to be. That assumption is doing real work and is rarely stated.
Agreed on all of that, and I have nothing to add to it.
What would change the position on repair peptides: adequately powered, published, peer-reviewed randomised controlled human trials with pre-specified outcomes. That is the standard applied to every other therapeutic claim on this site and it is the standard applied here.
The claim is narrower than it sounds, and deliberately so.
Collapsed as off-topic by two members at trust level 3 or above
This follows post #86 rather than contradicting it.
Practical experience of reading a preclinical wound-healing model, offered as one case with the conditions stated, not as a general finding. Conditions first, because they are what make it interpretable.
Worth separating two things that post #88 runs together.
A definition problem is doing most of the work in this reading a preclinical wound-healing model discussion. Once the term is pinned down I suspect the disagreement mostly goes away and what is left is small.